Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

By Sonal Singh, Y. Loke, C. Furberg. Journal of the American Medical Association (JAMA), 2007

855 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/174ca9deb77594f83d8f25ae73c5662dab958606

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Molecular Biology

Citations in the corpus

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2013, background): “Higher occurrence of fractures (29,30,33) Possibility of increased risk of myocardial infarction with rosiglitazone (31,108) Rare risk bladder cancer with pioglitazone (109)”
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. (2010, result): “Subsequently, meta-analyses by other authors were published, some of which confirmed these findings, while others reported inconclusive results.(12,13) The most comprehensive patient-level analysis was conducted by the FDA and confirmed an odds ratio (OR) of 1.”
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (2008, positive): “Several meta-analyses have suggested a 30–40% relative increase in risk for myocardial infarction [65, 66] with rosiglitazone.”
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009, background): “Several meta-analyses have suggested a 30 – 40% relative increase in risk for myocardial infarction (65,66) with rosiglitazone.”
Non-alcoholic fatty liver disease: the mist gradually clears. (2008, result): “A note of caution over the use of TZDs in the treatment of NASH has arisen recently as a result of several meta-analyses of trials of TZDs in T2DM patients that have consistently shown that rosiglitazone increases the incidence of myocardial infarction and heart failure [72].”
Standards of Medical Care in Diabetes—2008 (2008, background): “Of note, the consensus algorithm was developed before publications that raised concerns about increased risk of myocardial infarction with use of rosiglitazone (52,53) and before addition of black box warnings about congestive heart failure (CHF) for both rosiglitazone and pioglitazone.”